BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34970257)

  • 1. CD8
    Wu X; Jiang D; Liu H; Lu X; Lv D; Liang L
    Front Immunol; 2021; 12():745945. PubMed ID: 34970257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral CXCL13
    Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating CD39
    Qi Y; Xia Y; Lin Z; Qu Y; Qi Y; Chen Y; Zhou Q; Zeng H; Wang J; Chang Y; Bai Q; Wang Y; Zhu Y; Xu L; Chen L; Kong Y; Zhang W; Dai B; Liu L; Guo J; Xu J
    Cancer Immunol Immunother; 2020 Aug; 69(8):1565-1576. PubMed ID: 32306075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation of CD45RO+CD8+ T cells is a diagnostic and prognostic biomarker for clear cell renal cell carcinoma.
    Wu K; Zheng X; Yao Z; Zheng Z; Huang W; Mu X; Sun F; Liu Z; Zheng J
    Aging (Albany NY); 2021 May; 13(10):14304-14321. PubMed ID: 34016791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma.
    Zhang D; Ni Y; Wang Y; Feng J; Zhuang N; Li J; Liu L; Shen W; Zheng J; Zheng W; Qian C; Shan J; Zhou Z
    J Transl Med; 2023 Jul; 21(1):489. PubMed ID: 37474942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKG2A
    Qiu Y; Liu L; Jiang W; Xu Z; Wang J; Dai S; Guo J; Xu J
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38262706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of an immune-related prognostic model by exploring the tumor microenvironment of clear cell renal cell carcinoma.
    He J; Zhong Y; Sun Y; Xie C; Yu T
    Anal Biochem; 2022 Apr; 643():114567. PubMed ID: 35122734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stem/progenitor cell marker expression in clear cell renal cell carcinoma: a potential relationship with the immune microenvironment to be explored.
    Yoon JY; Gedye C; Paterson J; Ailles L
    BMC Cancer; 2020 Apr; 20(1):272. PubMed ID: 32245446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.
    Braun DA; Hou Y; Bakouny Z; Ficial M; Sant' Angelo M; Forman J; Ross-Macdonald P; Berger AC; Jegede OA; Elagina L; Steinharter J; Sun M; Wind-Rotolo M; Pignon JC; Cherniack AD; Lichtenstein L; Neuberg D; Catalano P; Freeman GJ; Sharpe AH; McDermott DF; Van Allen EM; Signoretti S; Wu CJ; Shukla SA; Choueiri TK
    Nat Med; 2020 Jun; 26(6):909-918. PubMed ID: 32472114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy.
    Bai D; Feng H; Yang J; Yin A; Qian A; Sugiyama H
    Cancer Sci; 2021 Jun; 112(6):2126-2139. PubMed ID: 33735492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.
    Şenbabaoğlu Y; Gejman RS; Winer AG; Liu M; Van Allen EM; de Velasco G; Miao D; Ostrovnaya I; Drill E; Luna A; Weinhold N; Lee W; Manley BJ; Khalil DN; Kaffenberger SD; Chen Y; Danilova L; Voss MH; Coleman JA; Russo P; Reuter VE; Chan TA; Cheng EH; Scheinberg DA; Li MO; Choueiri TK; Hsieh JJ; Sander C; Hakimi AA
    Genome Biol; 2016 Nov; 17(1):231. PubMed ID: 27855702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8 + T cell-based molecular subtypes with heterogeneous immune landscapes and clinical significance in acute myeloid leukemia.
    Zhong F; Yao F; Jiang J; Yu X; Liu J; Huang B; Wang X
    Inflamm Res; 2024 Mar; 73(3):329-344. PubMed ID: 38195768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma.
    Wei B; Yu M; Yao J; Jiang M; An J; Yang J; Lin J; Zhao Y; Zhu Y
    Front Immunol; 2021; 12():657951. PubMed ID: 34531849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of Multiparametric Evaluation of Immune-Related T-Cell Markers in Renal-Cell Carcinoma.
    Kawashima A; Uemura M; Nonomura N
    Clin Genitourin Cancer; 2019 Dec; 17(6):e1147-e1152. PubMed ID: 31473121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm.
    Luo J; Xie Y; Zheng Y; Wang C; Qi F; Hu J; Xu Y
    Cancer Med; 2020 Jun; 9(12):4310-4323. PubMed ID: 32311223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.
    Chen M; Nie Z; Huang D; Gao Y; Cao H; Zheng L; Zhang S
    Front Immunol; 2022; 13():1048204. PubMed ID: 36505496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma.
    Braun DA; Street K; Burke KP; Cookmeyer DL; Denize T; Pedersen CB; Gohil SH; Schindler N; Pomerance L; Hirsch L; Bakouny Z; Hou Y; Forman J; Huang T; Li S; Cui A; Keskin DB; Steinharter J; Bouchard G; Sun M; Pimenta EM; Xu W; Mahoney KM; McGregor BA; Hirsch MS; Chang SL; Livak KJ; McDermott DF; Shukla SA; Olsen LR; Signoretti S; Sharpe AH; Irizarry RA; Choueiri TK; Wu CJ
    Cancer Cell; 2021 May; 39(5):632-648.e8. PubMed ID: 33711273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating TNFRSF9
    Li Y; Wang Z; Jiang W; Zeng H; Liu Z; Lin Z; Qu Y; Xiong Y; Wang J; Chang Y; Bai Q; Wang Y; Liu L; Zhu Y; Xu L; Xia Y; Guo J; Xu J
    Oncoimmunology; 2020 Oct; 9(1):1838141. PubMed ID: 33178496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune classification of clear cell renal cell carcinoma.
    Su S; Akbarinejad S; Shahriyari L
    Sci Rep; 2021 Feb; 11(1):4338. PubMed ID: 33619294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.